A team of Goodwin attorneys recently advised Blueprint Medicines in a $50 million Series C financing. The financing was led by Partner Fund Management and will be used to fund the advancement of Blueprint Medicines’ two lead product candidates through clinical trials in 2015, as well as for the continued development of Blueprint Medicines’ kinase discovery platform and pipeline.
Blueprint Medicines, based in Cambridge, Mass., is a biotechnology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. Since its founding in 2011, the company has raised more than $115 million in VC funding.
The Goodwin team advising Blueprint was led by partners Kingsley Taft and Danielle Lauzon.
For more information about this financing, read the press release.